Cantabio Pharmaceuticals Inc. has announced that Dr. Gergely Toth, Chief Executive Officer, will present results of the company’s DJ-1 protein targeting small molecule pharmacological chaperone therapeutic programs at two conferences: the 4th World Parkinson’s Congress in Portland, Oregon on September 20-22; and, the 3rd International Parkinson’s Disease Symposium in Luxemburg on October 6-8. DJ-1 is one of the key proteins involved in the prevention and reduction of damage due to oxidative stress and protein misfolding in brain cells. Loss of DJ-1 protein function has been linked to the onset and progression of familial and sporadic PD and other neurodegenerative diseases. Rescuing cells from the loss of DJ-1 function could be a critical factor in progressing towards a viable treatment of PD. The presentations will describe the chemical microarray based high throughput binding screening applied for the identification of a diverse set of novel DJ-1 small molecule ligands, and characterization of one class of small molecule ligands and their positive biological activity in cellular and in vivo models of PD.